BioXcel Therapeutics (BTAI) Profit After Tax (2017 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly Profit After Tax of -$12.7 million for Q1 2026, down 74.95% year-over-year from -$50.7 million in Q1 2025, and down 1.16% quarter-over-quarter from -$12.5 million in Q4 2025.
BioXcel Therapeutics (BTAI) Profit After Tax (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Profit After Tax history runs 10 years deep, the most recent figure standing at -$12.7 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 74.95% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$75.3 million (down 88.04% YoY), while the FY2025 annual figure was -$69.9 million, down 17.28% from the prior year.
- Profit After Tax for Q1 2026 stood at -$12.7 million, down from -$12.5 million in the prior quarter.
- The five-year high for Profit After Tax was -$7.3 million in Q1 2025, with the low at -$54.8 million in Q4 2022.
- The 5-year median for Profit After Tax is -$26.8 million (2024), against an average of -$28.6 million.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 84.49% in 2024, then slumped 131.2% in 2025.
- BioXcel Therapeutics' Profit After Tax stood at -$54.8 million in 2022, then surged by 59.39% to -$22.3 million in 2023, then jumped by 51.21% to -$10.9 million in 2024, then slipped by 15.53% to -$12.5 million in 2025, then fell by 1.16% to -$12.7 million in 2026.
- Business Quant data shows BTAI's Profit After Tax at -$12.7 million in Q1 2026, -$12.5 million in Q4 2025, and -$30.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.93 Mn | 24.93 Mn | 160,000.00 | -14.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.71 Mn |
| Mar 31, 2026 | -12.69 Mn |
| Dec 31, 2025 | -12.55 Mn |
| Sep 30, 2025 | -30.91 Mn |
| Jun 30, 2025 | -19.19 Mn |
| Mar 31, 2025 | -7.25 Mn |
| Dec 31, 2024 | -10.86 Mn |
| Sep 30, 2024 | -13.65 Mn |
| Jun 30, 2024 | -8.30 Mn |
| Mar 31, 2024 | -26.79 Mn |
| Dec 31, 2023 | -22.26 Mn |
| Sep 30, 2023 | -50.49 Mn |
| Jun 30, 2023 | -53.52 Mn |
| Mar 31, 2023 | -52.80 Mn |
| Dec 31, 2022 | -54.81 Mn |
| Sep 30, 2022 | -41.81 Mn |
| Jun 30, 2022 | -37.67 Mn |
| Mar 31, 2022 | -31.47 Mn |
| Dec 31, 2021 | -26.13 Mn |
| Sep 30, 2021 | -26.81 Mn |